BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17874228)

  • 1. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
    Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
    Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of prostate cancer with finasteride.
    Ross RK; Skinner E; Cote RJ
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562807
    [No Abstract]   [Full Text] [Related]  

  • 5. Five-alpha-reductase Inhibitors for prostate cancer prevention.
    Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
    Villers A
    Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
    Cote RJ; Skinner EC; Salem CE; Mertes SJ; Stanczyk FZ; Henderson BE; Pike MC; Ross RK
    Br J Cancer; 1998 Aug; 78(3):413-8. PubMed ID: 9703292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of the PCPT from clinical to molecular analyses.
    Hoque A
    Nat Clin Pract Oncol; 2006 Nov; 3(11):581. PubMed ID: 17080169
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
    Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
    Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pathologist's perspective on the PCPT trial].
    Molinié V; Allory Y
    Prog Urol; 2008 Apr; 18 Suppl 3():S47-52. PubMed ID: 18455084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.
    Ankerst DP; Thompson IM
    Arch Ital Urol Androl; 2006 Dec; 78(4):125-9. PubMed ID: 17269614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer.
    Ankerst DP; Thompson IM
    Arch Ital Urol Androl; 2006 Dec; 78(4):154-6. PubMed ID: 17269622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Cancer Prevention Trial (PCPT) update.
    Coltman CA; Thompson IM; Feigl P
    Eur Urol; 1999; 35(5-6):544-7. PubMed ID: 10325520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    Mellon JK
    Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.